Physician profile
Laura Ispas
NPI 1548340748
$8,527.83
in general payments reported to CMS, 2019-2025
36 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $405 · 2021: $1,303 · 2022: $1,579 · 2023: $1,587 · 2024: $1,322 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,148 · Education: $56.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,147.93 |
| Education | $56.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,474.47 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,176.18 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $1,136.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $633.65 | 2021-2025 | Cuvitru, Glassia, Takhzyro |
| Amgen INC. | $585.58 | 2021-2025 | Tezspire, Otezla |
| Pfizer INC. | $441.57 | 2019-2023 | |
| Kaleo, INC. | $409.02 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $333.55 | 2019-2024 | Xolair |
| Genzyme Corporation | $299.55 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $262.73 | 2020-2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $223.86 | 2021-2025 | |
| Grifols USA, LLC | $214.14 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Ars Pharmaceuticals Operations, INC. | $183.46 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $158.84 | 2023-2025 | Ryaltris |
| Abbvie INC. | $137.27 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.67 | 2019-2022 | |
| Csl Behring | $98.78 | 2022-2025 | Haegarda, Andembry |
| Incyte Corporation | $77.58 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $55.26 | 2025 | Xhance, Nuzyra |
| Vifor Pharma, INC. | $48.40 | 2025 | Veltassa, Zemaira |
| Uswm, LLC | $48.00 | 2021 | |
| Shire North American Group INC | $41.64 | 2019 | |
| Pharming Healthcare, INC. | $39.03 | 2020-2023 | Ruconest |
| Greer Laboratories, INC. | $37.16 | 2019 | |
| Biocryst US Sales Co., LLC | $30.36 | 2022 | |
| Phadia US INC. | $30.04 | 2023 | Immunocap |
| Lilly USA, LLC | $28.90 | 2024 | Ebglyss |
| Azurity Pharmaceuticals, INC. | $28.07 | 2025 | Alvesco |
| Alk-Abello, INC | $25.19 | 2019 | |
| Aimmune Therapeutics, INC. | $24.30 | 2022 | |
| Mylan Specialty L.P. | $22.14 | 2022 | |
| Nabriva Therapeutics, Plc | $21.86 | 2022 | |
| Merck Sharp & Dohme LLC | $20.00 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $19.96 | 2020 | |
| Jubilant Hollisterstier LLC | $19.44 | 2025 | |
| Organon LLC | $19.37 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Ispas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.